Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B.

Blood. 2003 May 15;101(10):3849-56. Epub 2003 Jan 16.

2.

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B.

Br J Haematol. 2003 Jan;120(1):44-52.

PMID:
12492575
3.

Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.

Barlogie B Jr, Shaughnessy JD.

Int J Hematol. 2002 Aug;76 Suppl 1:337-9.

PMID:
12430877
4.

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Kaufmann H, Krömer E, Nösslinger T, Weltermann A, Ackermann J, Reisner R, Bernhart M, Drach J.

Eur J Haematol. 2003 Sep;71(3):179-83.

PMID:
12930318
5.

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.

Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J.

Br J Haematol. 2003 Aug;122(3):430-40.

PMID:
12877670
6.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.

Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON).; Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC)..

Br J Haematol. 2007 Feb;136(4):615-23.

PMID:
17223915
7.

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M.

Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17.

PMID:
22426624
8.

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J.

Br J Haematol. 2006 Oct;135(2):158-64. Epub 2006 Aug 25.

PMID:
16939489
9.

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M, Laï JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY; Intergroupe Francophone du Myélome..

Blood. 2001 Mar 15;97(6):1566-71.

10.

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.

Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom A, Gahrton G, Nahi H.

Oncol Rep. 2009 Jul;22(1):137-42.

PMID:
19513515
11.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.

Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54. doi: 10.1016/j.bbmt.2009.11.025. Epub 2010 Jan 18.

12.

Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma.

Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Höcker P, Gisslinger H, Lechner K, Kalhs P, Drach J.

Ann Hematol. 2001 Jun;80(6):345-8.

PMID:
11475148
13.

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfão A.

Blood. 1998 May 1;91(9):3366-71.

14.

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2007 Jun;137(6):530-6. Epub 2007 May 9.

PMID:
17489983
15.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G.

Blood. 2003 Sep 1;102(5):1588-94. Epub 2003 May 1.

16.

Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.

Harrison CJ, Mazzullo H, Cheung KL, Gerrard G, Jalali GR, Mehta A, Osier DG, Orchard KH.

Br J Haematol. 2003 Mar;120(6):944-52.

PMID:
12648063
17.

[Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].

Deng SH, Xu Y, Wang YF, Mai YJ, Liu XP, Zhao YZ, Zou DH, Wang Y, Qiu LG.

Zhonghua Yi Xue Za Zhi. 2007 Jun 26;87(24):1685-8. Chinese.

PMID:
17825148
18.

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle R.

Blood. 2005 Nov 15;106(10):3553-8. Epub 2005 Jul 19.

19.

Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma.

Calasanz MJ, Cigudosa JC, Odero MD, García-Foncillas J, Marín J, Ardanaz MT, Rocha E, Gullón A.

Br J Haematol. 1997 Aug;98(2):418-25.

PMID:
9266942
20.

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J.

Blood. 2006 Apr 1;107(7):2633-8. Epub 2005 Dec 1.

Supplemental Content

Support Center